2/20/2013

Patients with certain genotypes of hepatitis C who took Gilead Sciences' sofosbuvir in a late-stage clinical trial had cure rates of 50% at 12 weeks and 73% at 16 weeks, compared with the 25% historic cure rate among such patients. Sofosbuvir-treated patients with cirrhosis showed lower sustained virologic response, researchers said.

Full Story:
Yahoo

Related Summaries